longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Clene (CLNN) Gets a Buy from JonesTrading

Tip Ranks
May 15, 2026 at 12:40 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

JonesTrading analyst Justin Walsh has reiterated a Buy rating on Clene (CLNN) with a price target of $30.00. Canaccord Genuity also maintains a Buy rating with a $50.00 target. Walsh, a 5-star analyst, has an average return of 19.9% and a 38.79% success rate, focusing on the Healthcare sector.

JonesTrading analyst Justin Walsh reiterated a Buy rating on Clene today and set a price target of $30.00.

Claim 55% Off TipRanks

  • Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
  • Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Walsh is a 5-star analyst with an average return of 19.9% and a 38.79% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Praxis Precision Medicines, and Atai Beckley N.V..

In a report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $50.00 price target.

Login to unlock196characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Sep 8, 2026 at 12:14 PMAI-era DCI: Beyond the chip, compete as a network. Is there a China play?
  • Apr 20, 2026 at 06:34 PMEli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy …
  • Apr 18, 2026 at 12:54 AMIn Just 11 Days, U.S. Stocks Move from 'Oversold' to 'Overbought' — A Rare Occurrence in History
  • Apr 16, 2026 at 11:12 AMUS Stocks Hit New Highs, Retail Investors Miss Out en masse: Tom Lee Says Next Rally Will Be Led by Them
  • Apr 13, 2026 at 01:07 AMU.S. Stocks Face a "Final Battle" as Hormuz Outcome Decides the Game: The Rash Never Win, the Patient Prevail

Related Stocks

Clene

Clene

USCLNN

-1.10%

Perspective Therapeutics

Perspective Therapeutics

USCATX

Praxis Precision Medicines

Praxis Precision Medicines

USPRAX

LongbridgeAI